Lifeboat Foundation

Dr Michael Fossel comments on the recent Bioviva announcement of the first human gene therapy against aging.

The other day, a friend of mine, Liz Parrish, the CEO and founder of BioViva, made quite a splash when she injected herself with a viral vector containing genes for both telomerase and FST. Those in favor of what Liz did applaud her for her courage and her ability to move quickly and effectively in a landscape where red tape and regulatory concerns have – in the minds of some – impeded innovation and medical care. Those opposed to what Liz did have criticized her for moving too rapidly without sufficient concern for safety, ethics, or (from some critics) scientific rationale.

Many people have asked me to comment, both as an individual and as the founder of Telocyte. This occurs for two reasons. For one thing, I was the first person to ever advocate the use of telomerase as a clinical intervention, in discussions, in published journal articles, and in published books. My original JAMA articles (1997 and 1998), my first book on the topic (1996), and my textbook (2004) all clearly explained both the rational of and the implications for using telomerase as a therapeutic intervention to treat age-related disease. For another thing, Liz knew that our biotech firm, Telocyte, intends to do almost the same thing, but with a few crucial differences: we will only be using telomerase (hTERT) and we intend to pursue human trials that have FDA clearance, have full IRB agreement, and meet GMP (“Good Medical Production”) standards.

We cannot help but applaud Liz’s courage in using herself as a subject, a procedure with a long (and occasionally checkered) history in medical science. Using herself as the subject undercuts much of the ethical criticism that would be more pointed if she used other patients. Like many others, we also fully understand the urgent need for more effective therapeutic interventions: patients are not only suffering, but dying as we try to move ahead. In the case of Alzheimer’s disease, for example (our primary therapeutic target at Telocyte), there are NO currently effective therapies, a history of universal failure in human trials for experimental therapies, and an enormous population of patients who are currently losing their souls and their lives to this disease. A slow, measured approach to finding a cure is scarcely welcome in such a context.

Read more

What the nervous system of the roundworm, frozen embryos, and extreme hypothermia tell us about preserving the mind.

Read more

The first attempt at using gene therapy to prevent regular aging allegedly happened last month in what could spell the beginning of a new era in do-it-yourself genetic modification.

CEO and founder of BioViva Sciences USA Inc, Liz Parrish, claims she underwent gene therapy at an undisclosed location in Latin America where she received two forms of treatment, including muscle mass enhancement and therapy to increase the length of the telomeres, the DNA caps which protect the chromosome from deterioration and are associated with longer life span.

Parrish announced in a Reddit AMA that she had gone through the therapy and if successful she plans to roll out a public offering in three to five years despite neither treatment being FDA approved. The results of the therapy are yet unknown and she says she feels no different so far but believes it will be months before any changes occur. If successful her body, in theory, should begin to de-age.

Read more

We all have different circadian rhythms but they slow down during aging, and we may be able to do something about it.

Your body is in a state of constant flux and the circadian rhythm is its master regulator, controlling everything from sleep cycles to appetite and beyond. Jet lag is a side effect of a confused internal cycle as it adjusts to a new timetable. Shift work and irregular patterns of activity can also potentially cause some serious problems if sustained for a long period, including raising risk of type 2 diabetes, dementia and all cause mortality.

When researchers studied aging mice, they saw a progressive decline in levels of molecules called polyamines. These are involved with a number of processes, but particularly in cell growth and circadian rhythm. The drop in polyamines also coincided with a slowing of their circadian cycle — which increased disease risk.

Read more

Can we, as adults, grow new neurons? Neuroscientist Sandrine Thuret says that we can, and she offers research and practical advice on how we can help our brains better perform neurogenesis—improving mood, increasing memory formation and preventing the decline associated with aging along the way.

Listen/View

Read more

Scientists have managed to grow a miniature brain, and there’s a whole bunch of other so called ‘organoids’ we’re currently learning to perfect. We can now add kidneys to the tick box.

There have been a few mini-organ breakthroughs lately, and now we can grow simple kidneys in the lab too.

Regenerative medicine has incredible promise and provides hope that one day virtually any injury could be corrected. Scientists have managed to grow a miniature brain, and there’s a whole bunch of other so called ‘organoids’ we’re currently learning to perfect. We can now add kidneys to the tick box.

Read more

Hello, everyone. i got a nice invite to join and post a few items from elsewhere. I already see a few familiar folks who frequent the same pages. So excuse me while I “spam” things up a bit. First up:

The last line is an interesting one. If you look up the limits of memory you get a variety of answers. Hundreds of years perhaps? I think maybe some other technology will take care of that. I don’t know that it’ll be smart dust, a neural net, artificial neurons dedicated to memory or some combination. Can’t wait to find out.

Sea anemones may not look like humans but it seems they have a common ancestor, and they may also hold the key to eternal youth.

Read more

Scientists have discovered more than 200 genes linked to ageing and have found switching them off extends life.

Read more

BioViva made headlines last week after announcing that they had become the first company to administer anti-aging gene therapy on a human subject. But missing from the press release was exactly how this would work, the likelihood of its success, and the consequences. How better to address this then, than to hear from ‘Patient 0’ herself, Liz Parrish, the company’s CEO who will be undertaking the treatment.

Yesterday (October 11), she took part in a Reddit AMA (Ask Me Anything), answering a range of questions submitted by Reddit users seeking to find out more about this supposedly pioneering study.

Here are ten things we learned from Liz Parrish’s Reddit AMA.

Read more